About Us
Management
David Pompliano, Ph.D., CEO
David has nineteen years of leadership experience in the pharmaceutical industry with a strong track record in joint venture management, international business development, and driving strategic change in research and development. Most recently he served as Vice President, Worldwide Basic Head, Vaccines and Infectious Diseases Franchise for Merck Research Laboratories, where he created the global antimicrobial research strategy and led the research and business development teams that integrated internal discovery activities with external shared-risk venture partners. Prior to Merck, David was Vice President, Head of Biology, Microbial Musculoskeletal and Proliferative Diseases Center for Excellence in Drug Discovery at GlaxoSmithKline. As a drug hunter, David has contributed to the discovery or development of four marketed drugs (Tykerb, Promacta, Votrient and Altabax) and four drugs that have reached clinical proof of concept. David has published >50 research papers and is co-inventor on 3 patents. David earned his Ph.D. in Chemistry from Stanford University and was an NIH Postdoctoral Fellow at Harvard University.
John Kulp, Ph.D., Founder/CTO
John has a broad background including senior management positions with responsibility for product development, research, operations, business development, and strategic planning. He has a 10-year background in BioLeap’s core technologies, achieving several innovations in fragment-protein simulations and fragment-based design tools. He founded the large-scale biophysical simulation team at Sarnoff Corp., where he was Vice President, and has played a leading role in a number of successful business launches, including Symbolics and Locus Pharmaceuticals. John’s Ph.D. is in Electrical Science (statistical physics) from MIT.
Ian Cloudsdale, Ph.D., Vice President Chemistry
Ian has a broad background including senior management positions within the pharmaceutical, agrochemical and biotechnology industries. He has over 20 years of experience with Syngenta, Novartis and Sandoz. Ian’s PhD is from Cambridge University in Synthetic Chemistry and he has over 3 years experience with BioLeap’s CFBDD.